CYCLOBENZAPRINE HYDROCHLORIDE (sye-kloe-ben'za-preen) Cycoflex, Flexeril Classifications: autonomic nervous system agent; skeletal muscle relaxant, central acting Pregnancy Category: B
|
5 mg, 10 mg tablets
Structurally and pharmacologically related to tricyclic antidepressants. Relieves skeletal muscle spasm of local origin without
interfering with muscle function. Believed to act primarily within CNS at brain stem; some action at spinal cord level is
also probable. Depresses tonic somatic motor activity, although both gamma and alpha motor neurons are affected.
In common with other tricyclic compounds, it increases circulating norepinephrine by blocking its synaptic reuptake, thus
producing its antidepressant effect. Also has sedative effects and potent central and peripheral anticholinergic activity.
Short-term adjunct to rest and physical therapy for relief of muscle spasm associated with acute musculoskeletal conditions.
Not effective in treatment of spasticity associated with cerebral palsy or cerebral or cord disease.
Acute recovery phase of MI, patients with cardiac arrhythmias, heart block or conduction disturbances, CHF, hyperthyroidism.
Use for periods longer than 2 or 3 wk not recommended by manufacturer. Pregnancy (category B), lactation. Safe use in children
<15 y not established.
Patients receiving anticholinergic medications; prostatic hypertrophy, history of urinary retention, angle-closure glaucoma;
increased IOP, seizures; cardiovascular disease; hepatic impairment; older adults, debilitated patients; history of psychiatric
illness.
Muscle Spasm Adult: PO 510 mg t.i.d. (max: 60 mg/d) Geriatric: Start with 5 mg
Mild Hepatic Impairment Start with 5 mg
Moderate to Severe Hepatic Impairment Not recommended
|
Oral
- Do not administer drug if patient is receiving an MAO INHIBITOR (e.g., furazolidone, isocarboxazid, pargyline, tranylcypromine).
- Cyclobenzaprine is intended for short-term (2 or 3 wk) use.
- Store in tightly closed container, preferably at 15°30° C (59°86° F) unless otherwise directed
by manufacturer.
Body as a Whole:
Edema of tongue and face, sweating, myalgia, hepatitis, alopecia. Shares toxic potential of tricyclic antidepressants. CV: Tachycardia, syncope, palpitation, vasodilation, chest pain, orthostatic hypotension, dyspnea; with high doses, possibility
of severe arrhythmias. GI:
Dry mouth, indigestion, unpleasant taste, coated tongue, tongue discoloration, vomiting, anorexia, abdominal pain, flatulence, diarrhea,
paralytic ileus. CNS:
Drowsiness, dizziness, weakness, fatigue, asthenia, paresthesias, tremors, muscle twitching, insomnia, euphoria, disorientation, mania, ataxia. Skin: Pruritus, urticaria, skin rash. Urogenital: Increased or decreased libido, impotence.
Drug:
Alcohol,
barbiturates, other cns depressants enhance CNS depression; potentiates anticholinergic effects of phenothiazine and other anticholinergics; mao inhibitors may precipitate hypertensive crisisuse with extreme caution.
Absorption: Well absorbed from GI tract with some first-pass elimination in liver. Onset: 1 h. Peak: 38 h. Duration: 1224 h. Distribution: Highly protein bound (93%). Metabolism: Metabolized in liver to inactive metabolites. Elimination: Slowly excreted in urine with some elimination in feces; may be excreted in breast milk. Half-Life: 13 d.
Assessment & Drug Effects
- Supervision of ambulation may be indicated, especially in the older adult because of risk of drowsiness and dizziness.
- Withhold drug and notify physician if signs of hypersensitivity, e.g., pruritus, urticaria, rash, appear.
Patient & Family Education
- Avoid driving and other potentially hazardous activities until reaction to drug is known. Adverse effects include drowsiness
and dizziness.
- Avoid alcohol and other CNS DEPRESSANTS (unless otherwise directed by physician) because cyclobenzaprine enhances their effects.
- Dry mouth may be relieved by increasing total fluid intake (if not contraindicated).
- Keep physician informed of therapeutic effectiveness. Spasmolytic effect usually begins within 1 or 2 d and may be manifested
by lessening of pain and tenderness, increase in range of motion, and ability to perform ADL.
- Do not breast feed while taking this drug.